Janus Henderson Global Life Sciences Fund
JNGLX
NASDAQ- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Janus Henderson Global Life Sciences Fund (JNGLX) is an open-end mutual fund that seeks long-term growth of capital by investing primarily in equity securities of companies engaged in life sciences industries worldwide. The fund focuses on biotechnology, pharmaceuticals, healthcare services, medical devices, diagnostics, and life sciences tools; it employs a fundamental, bottom-up research process to select stocks with strong growth prospects, competitive advantages, and attractive valuations. Managed by Janus Henderson Investors, the fund provides diversified exposure across market capitalizations, with a portfolio typically comprising 50-80 holdings selected from developed and emerging markets globally. Established in 2000 as the Janus Global Life Sciences Fund and headquartered in Denver, Colorado (with additional key offices in London and Singapore following the 2017 merger of Janus Capital Group and Henderson Group), the fund operates under the broader Janus Henderson Investors platform, which manages over $400 billion in assets across various asset classes. It targets institutional and retail investors seeking sector-specific growth in the healthcare and life sciences sectors, which represent innovative areas addressing aging populations, novel therapies, and technological advancements in medicine. Recent developments include the fund's continued adaptation to market shifts, such as increased allocations to gene therapy, precision medicine, and digital health companies amid post-pandemic biotech recovery; in 2024, it benefited from strategic portfolio adjustments amid regulatory approvals for key holdings like CRISPR Therapeutics and Vertex Pharmaceuticals. No major name changes, acquisitions, or funding rounds directly affect the fund itself, as it remains a product of Janus Henderson, which announced enhanced ESG integration in its life sciences strategies in late 2024. The fund maintains a global footprint, with significant investments in U.S., European, and Asian life sciences firms.